Dietary Oxalate and Innate Immunity in Kidney Stone Disease

May 5, 2025 updated by: Tanecia Mitchell, PhD, University of Alabama at Birmingham
This study will test whether oxalate stimulates urinary crystals and impacts the immune system in healthy subjects using two controlled diets (low and high oxalate).

Study Overview

Status

Active, not recruiting

Conditions

Detailed Description

Oxalate is a small molecule found in plants and plant-derived food. It has been shown that meals containing high amounts of oxalate can increase urinary oxalate excretion, which is a risk factor for calcium oxalate kidney stones (CaOx KS). Small increases in oxalate can stimulate urinary crystals to form which can elicit an immune response. This study consists of having healthy subjects consume both low and oxalate enriched diets to evaluate the effect of oxalate on urinary crystals and immune responses. Participants will receive a low or high oxalate diet for 4 days prior to having a wash out period for 6 days. Participants will then crossover to the opposite oxalate diet for four more days.

Study Type

Interventional

Enrollment (Estimated)

20

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Alabama
      • Birmingham, Alabama, United States, 35233
        • University of Alabama at Birmingham

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 60 years (Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Healthy subjects (men and women) between the ages of 18 and 60 years of age
  • No calcium oxalate kidney stones or other medical conditions
  • Normal comprehensive metabolic panel (CMP)
  • Non tobacco users
  • Not pregnant
  • BMI between 20-30 kg/m2
  • Willing to abstain from vigorous exercise and vitamins/supplements during the study
  • Willing to consume only provided diets, accurately collect 24-hour urine samples, and have blood drawn

Exclusion Criteria:

  • Inability to sign and read the informed consent
  • Any medical, psychiatric, or social conditions that would prohibit participants from abiding by the study requirements
  • Physician refusal
  • Pregnant women
  • Active medical problems
  • History of kidney stones or any medical condition that could influence absorption or excretion of oxalate
  • Tobacco users
  • Taking medications or dietary supplements
  • BMI >30 or <20

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Low Oxalate Diet Followed by High Oxalate Diet
Subjects will consume a low oxalate diet for four days, with blood and 24-hour urine collections occurring at baseline and post diet. A ten day wash out period will follow, during which the subject will consume a self-selected diet. Subjects will then consume the high oxalate diet for the final four days, with blood and 24-hour urine collections once again occurring at baseline and post diet.
Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein. Participants will be asked not to take any dietary supplements, to exercise strenuously, or to consume food or drink that is not provided to them
Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein. Participants will be asked not to take any dietary supplements, to exercise strenuously, or to consume food or drink that is not provided to them.
Experimental: High Oxalate Diet Followed by Low Oxalate Diet
Subjects will consume a high oxalate diet for four days, with blood and 24-hour urine collections occurring at baseline and post diet. A ten day wash out period will follow, during which the subject will consume a self-selected diet. Subjects will then consume the low oxalate diet for the final four days, with blood and 24-hour urine collections once again occurring at baseline and post diet.
Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein. Participants will be asked not to take any dietary supplements, to exercise strenuously, or to consume food or drink that is not provided to them
Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein. Participants will be asked not to take any dietary supplements, to exercise strenuously, or to consume food or drink that is not provided to them.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Urinary Oxalate
Time Frame: Days 3-4 and 13-14
Twenty-four hour urinary oxalate will be reported as mg/day.
Days 3-4 and 13-14
Change in Crystalluria
Time Frame: Days 3-4 and 13-14
Crystalluria will be reported as particles/ml.
Days 3-4 and 13-14
Change in Monocyte Cellular Energetics and Mitochondrial Function
Time Frame: Days 1, 4, 11, and 14
Cellular energetics and mitochondrial function will be reported as oxygen consumption rate (pmol/min/10,000 cells).
Days 1, 4, 11, and 14
Change in Monocyte Subtypes
Time Frame: Days 1, 4, 11, and 14
Monocyte subtypes will be determined using flow cytometry (mean fluorescence intensity).
Days 1, 4, 11, and 14
Change in Monocyte Transcriptomics
Time Frame: Days 1, 4, 11, and 14
Monocyte cellular transcriptomics will be determined using RNA sequencing (mRNA).
Days 1, 4, 11, and 14

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Tanecia Mitchell, PhD, University of Alabama at Birmingham

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 5, 2021

Primary Completion (Estimated)

May 1, 2026

Study Completion (Estimated)

May 1, 2026

Study Registration Dates

First Submitted

August 1, 2019

First Submitted That Met QC Criteria

August 7, 2019

First Posted (Actual)

August 9, 2019

Study Record Updates

Last Update Posted (Actual)

May 8, 2025

Last Update Submitted That Met QC Criteria

May 5, 2025

Last Verified

May 1, 2025

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Kidney Stone

Clinical Trials on Low Oxalate Diet

Subscribe